.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma crease, taking up the leading science area at Sanofi.Quigley will start Sept. 30 as the French Big Pharma’s main scientific officer and worldwide head of research study, Sanofi informed Intense Biotech in an emailed statement.Quigley is substituting Frank Nestle, M.D., who left Sanofi this springtime amid a global overhaul of the company’s R&D system. Nestle, that spent 8 years along with the pharma, leapt over to Deerfield Management, where he currently serves as a companion on the therapeutics team as well as chief executive officer of the organization’s restorative revelation and also progression functions.
Quigley will definitely participate in Sanofi coming from a San Francisco-based biotech that resides in secrecy, according to his LinkedIn profile page. He is actually presently noted as the provider’s founder, president and also chief executive officer.Due to the fact that August 2021, Quigley has actually served as a venture companion at SV Health and wellness Investors, a medical care fund supervisor with existing expenditures in biotechs like BioAge, Cerevance, Dualitas Therapeutics and also Nimbus Therapies, and many more. Quigley previously held the top spot at Dualitas, a biotech that remains in secrecy, according to STAT.The future Sanofi leader also previously helmed Therini Bio, an immunotherapy biotech functioning to cultivate treatments for neurodegenerative ailments steered through vascular disorder.Prior to investing the final handful of years in biotech, Quigley possesses an also longer track record in Significant Pharma, very most just recently functioning as Gilead’s senior bad habit president of research the field of biology up until the summer of 2021.
Before that, he appeared greater than four years all over various leadership tasks at Bristol Myers Squibb and also functioned as a clinical supervisor at Johnson & Johnson’s Janssen upper arm before that.Sanofi said Quigley’s purpose in his new job will be to “maximize our chance of success through optimum partnerships all over our company as well as beyond, carrying best-in-class development and also developing and sourcing new industry-leading ability along with a commitment to range,” according to an interior memorandum secured by STAT.